{"id":501631,"date":"2021-06-08T07:05:14","date_gmt":"2021-06-08T11:05:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-set-to-join-russell-3000-index\/"},"modified":"2021-06-08T07:05:14","modified_gmt":"2021-06-08T11:05:14","slug":"summit-therapeutics-set-to-join-russell-3000-index","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-set-to-join-russell-3000-index\/","title":{"rendered":"Summit Therapeutics set to join Russell 3000\u00ae Index"},"content":{"rendered":"
\n

Cambridge, MA, June 08, 2021 (GLOBE NEWSWIRE) — Summit Therapeutics Inc. (NASDAQ: SMMT) is set to join the broad-market Russell 3000\u00ae Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US markets open on June 28, according to a preliminary list of additions posted by FTSE Russell.<\/p>\n

Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 7, ranking them by total market capitalization. \u00a0Membership in the US all-cap Russell 3000\u00ae Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000\u00ae Index or small-cap Russell 2000\u00ae Index, as well as the appropriate growth and value style indexes. \u00a0FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.<\/p>\n

\u201cAs we continue our progress in our mission to become a leader in resolving high unmet medical needs, we appreciate the full commitment this requires of Team Summit,\u201d said Robert W. Duggan, our Chairman and Chief Executive Officer.\u00a0 \u201cOur inclusion within the Russell 3000\u00ae Index represents the recognition of the work Team Summit has put in thus far in the important journey to achieve our mission.\u201d<\/p>\n

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. \u00a0Approximately $10.6 trillion in assets are benchmarked against Russell\u2019s US indexes.\u00a0 Russell indexes are part of FTSE Russell, a leading global index provider.<\/p>\n

For more information on the Russell 3000\u00ae Index and the Russell indexes reconstitution,\u00a0please visit\u00a0the \u201cRussell Reconstitution\u201d section on the FTSE Russell website.<\/p>\n

\n \n <\/p>\n

\n About Summit Therapeutics<\/strong>
\n
Summit Therapeutics, empowered by its Discuva Platform, the Company\u2019s innovative antibiotic discovery engine, supported by BARDA and CARB-X funding, intends to be the leader in patient-friendly and paradigm-shifting treatments for infectious diseases and other significant unmet medical needs while being an ally to physicians.\u00a0 Our new mechanism pipeline product candidates are designed with the goal to become the patient-friendly, new-era standard of care, by working in harmony with the human microbiome to treat prospective patients suffering from infectious disease, initially focusing on Clostridioides difficile<\/i> infections (CDI).\u00a0 The overriding objective of Summit Therapeutics is to create value for patients, hospital caregivers, and community-based healthcare providers, as well as healthcare payers around the world.\u00a0 We seek to create value by developing drugs with high therapeutic efficacy – curing the cause of the patient’s condition with minimal or zero disease recurrence or antimicrobial resistance, for the longest extent possible – and minimizing the trauma caused to the patient and healthcare ecosystem by minimizing serious side effects, disease recurrence, and inaccessibility to our treatments as a result of financial or other barriers.\u00a0 Currently, Summit\u2019s lead product candidate, ridinilazole, is engaged in two pivotal global Phase 3 trials, Ri-CoDIFy 1 & 2, each enrolling approximately 680 patients vs. the standard of care (vancomycin) for the treatment and reduction of recurrence of C. difficile<\/i> infections, in addition to an adolescent trial, Ri-CoDIFy 3.\u00a0 Commercialization of ridinilazole for the treatment and the reduction of recurrence of CDI is subject to regulatory approvals.\u00a0 SMT-738, the second candidate within Summit\u2019s portfolio, is currently in the IND-enabling phase for the treatment of multidrug resistant infections, specifically those caused by carbapenem-resistant Enterobacteriaceae (CRE).<\/p>\n

For more information, please visit www.summittxinc.com and follow us on Twitter @summitplc. For more information on the Company\u2019s Discuva Platform, please visit https:\/\/www.summittxinc.com\/our-science\/discuva-platform.<\/p>\n

\n Contact Summit Investor Relations<\/b>
\n
Dave Gancarz
Head of Investor Relations & Corporate Strategy
david.gancarz@summitplc.com<\/p>\n

General Inquiries:\u00a0
investors@summitplc.com<\/p>\n

\n
\n
\n <\/b>\n <\/p>\n

\n About FTSE Russell<\/b>
\n
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. <\/p>\n

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $17.9 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. <\/p>\n

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. <\/p>\n

FTSE Russell is wholly owned by London Stock Exchange Group. <\/p>\n

For more information, visit www.ftserussell.com<\/u><\/a>.<\/p>\n

\n \n <\/p>\n

\n Summit Forward-looking Statements<\/strong>
\n
Any statements in this press release about the Company\u2019s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company\u2019s product candidates, the therapeutic potential of the Company\u2019s product candidates, the potential commercialization of the Company\u2019s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the impact of the COVID-19 pandemic on the Company\u2019s operations and clinical trials and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, global public health crises, including the coronavirus COVID-19 outbreak, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company\u2019s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of filings that the Company makes with the Securities and Exchange Commission. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company\u2019s views only as of the date of this release and should not be relied upon as representing the Company\u2019s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release. <\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Cambridge, MA, June 08, 2021 (GLOBE NEWSWIRE) — Summit Therapeutics Inc. (NASDAQ: SMMT) is set to join the broad-market Russell 3000\u00ae Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US markets open on June 28, according to a preliminary list of additions posted by FTSE Russell. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 7, ranking them by total market capitalization. \u00a0Membership in the US all-cap Russell 3000\u00ae Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000\u00ae Index or small-cap Russell 2000\u00ae Index, as well as the appropriate growth and value style indexes. \u00a0FTSE Russell determines membership for its Russell indexes primarily … <\/p>\n

Continue reading “Summit Therapeutics set to join Russell 3000\u00ae Index”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-501631","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSummit Therapeutics set to join Russell 3000\u00ae Index - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-set-to-join-russell-3000-index\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Summit Therapeutics set to join Russell 3000\u00ae Index - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Cambridge, MA, June 08, 2021 (GLOBE NEWSWIRE) — Summit Therapeutics Inc. (NASDAQ: SMMT) is set to join the broad-market Russell 3000\u00ae Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US markets open on June 28, according to a preliminary list of additions posted by FTSE Russell. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 7, ranking them by total market capitalization. \u00a0Membership in the US all-cap Russell 3000\u00ae Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000\u00ae Index or small-cap Russell 2000\u00ae Index, as well as the appropriate growth and value style indexes. \u00a0FTSE Russell determines membership for its Russell indexes primarily … Continue reading "Summit Therapeutics set to join Russell 3000\u00ae Index"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-set-to-join-russell-3000-index\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-08T11:05:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MDUxMSM0MjMyMjk0IzIyMDkzODM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-set-to-join-russell-3000-index\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-set-to-join-russell-3000-index\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Summit Therapeutics set to join Russell 3000\u00ae Index\",\"datePublished\":\"2021-06-08T11:05:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-set-to-join-russell-3000-index\\\/\"},\"wordCount\":1117,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-set-to-join-russell-3000-index\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MDUxMSM0MjMyMjk0IzIyMDkzODM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-set-to-join-russell-3000-index\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-set-to-join-russell-3000-index\\\/\",\"name\":\"Summit Therapeutics set to join Russell 3000\u00ae Index - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-set-to-join-russell-3000-index\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-set-to-join-russell-3000-index\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MDUxMSM0MjMyMjk0IzIyMDkzODM=\",\"datePublished\":\"2021-06-08T11:05:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-set-to-join-russell-3000-index\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-set-to-join-russell-3000-index\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-set-to-join-russell-3000-index\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MDUxMSM0MjMyMjk0IzIyMDkzODM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI1MDUxMSM0MjMyMjk0IzIyMDkzODM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/summit-therapeutics-set-to-join-russell-3000-index\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Summit Therapeutics set to join Russell 3000\u00ae Index\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Summit Therapeutics set to join Russell 3000\u00ae Index - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-set-to-join-russell-3000-index\/","og_locale":"en_US","og_type":"article","og_title":"Summit Therapeutics set to join Russell 3000\u00ae Index - Market Newsdesk","og_description":"Cambridge, MA, June 08, 2021 (GLOBE NEWSWIRE) — Summit Therapeutics Inc. (NASDAQ: SMMT) is set to join the broad-market Russell 3000\u00ae Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US markets open on June 28, according to a preliminary list of additions posted by FTSE Russell. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 7, ranking them by total market capitalization. \u00a0Membership in the US all-cap Russell 3000\u00ae Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000\u00ae Index or small-cap Russell 2000\u00ae Index, as well as the appropriate growth and value style indexes. \u00a0FTSE Russell determines membership for its Russell indexes primarily … Continue reading \"Summit Therapeutics set to join Russell 3000\u00ae Index\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-set-to-join-russell-3000-index\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-08T11:05:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MDUxMSM0MjMyMjk0IzIyMDkzODM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-set-to-join-russell-3000-index\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-set-to-join-russell-3000-index\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Summit Therapeutics set to join Russell 3000\u00ae Index","datePublished":"2021-06-08T11:05:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-set-to-join-russell-3000-index\/"},"wordCount":1117,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-set-to-join-russell-3000-index\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MDUxMSM0MjMyMjk0IzIyMDkzODM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-set-to-join-russell-3000-index\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-set-to-join-russell-3000-index\/","name":"Summit Therapeutics set to join Russell 3000\u00ae Index - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-set-to-join-russell-3000-index\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-set-to-join-russell-3000-index\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MDUxMSM0MjMyMjk0IzIyMDkzODM=","datePublished":"2021-06-08T11:05:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-set-to-join-russell-3000-index\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-set-to-join-russell-3000-index\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-set-to-join-russell-3000-index\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MDUxMSM0MjMyMjk0IzIyMDkzODM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI1MDUxMSM0MjMyMjk0IzIyMDkzODM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/summit-therapeutics-set-to-join-russell-3000-index\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Summit Therapeutics set to join Russell 3000\u00ae Index"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/501631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=501631"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/501631\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=501631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=501631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=501631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}